Renuka Iyer

Summary

Affiliation: Roswell Park Cancer Institute
Country: USA

Publications

  1. doi request reprint Erlotinib and radiation therapy for elderly patients with esophageal cancer - clinical and correlative results from a prospective multicenter phase 2 trial
    Renuka Iyer
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Oncology 85:53-8. 2013
  2. doi request reprint A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor
    Renuka Iyer
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Expert Opin Pharmacother 11:311-20. 2010
  3. ncbi request reprint A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study
    Renuka V Iyer
    Department of Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA
    Ann Surg Oncol 14:3202-9. 2007
  4. doi request reprint Sorafenib: a clinical and pharmacologic review
    Renuka Iyer
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Expert Opin Pharmacother 11:1943-55. 2010
  5. ncbi request reprint Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease
    Renuka V Iyer
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Biol Blood Marrow Transplant 11:587-92. 2005
  6. ncbi request reprint Surgical resection after TNFerade therapy for locally advanced pancreatic cancer
    Manpreet K Chadha
    Department of Medicine, Roswell Park Cancer Institute and State University of New York at Buffalo, Buffalo, NY, USA
    JOP 10:535-8. 2009
  7. ncbi request reprint Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report
    Anubha Bharthuar
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    JOP 10:523-7. 2009
  8. ncbi request reprint Chemoradiation is a tolerable therapy for older adults with esophageal cancer
    Sujatha Nallapareddy
    Roswell Park Cancer Institute, Elm and Carlton Sts, Buffalo, NY 14263, USA
    Anticancer Res 25:3055-60. 2005
  9. ncbi request reprint Cystic pancreatic tumors (CPT): predictors of malignant behavior
    Milind Javle
    Department of Medicine, Roswell Park Cancer Institute, and State University at Buffalo, Buffalo, New York 14263, USA
    J Surg Oncol 95:221-8. 2007
  10. ncbi request reprint Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer
    Veena Watwe
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Am J Clin Oncol 28:560-4. 2005

Collaborators

Detail Information

Publications23

  1. doi request reprint Erlotinib and radiation therapy for elderly patients with esophageal cancer - clinical and correlative results from a prospective multicenter phase 2 trial
    Renuka Iyer
    Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Oncology 85:53-8. 2013
    ..Elderly patients with esophageal cancer who are not candidates for chemoradiation may benefit from targeted agents; hence erlotinib combined with radiotherapy was evaluated in this trial...
  2. doi request reprint A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor
    Renuka Iyer
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Expert Opin Pharmacother 11:311-20. 2010
    ....
  3. ncbi request reprint A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study
    Renuka V Iyer
    Department of Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA
    Ann Surg Oncol 14:3202-9. 2007
    ..To determine the clinical benefit response (CBR), time to tumor progression (TTP), overall survival, and effect on quality of life (QOL) of gemcitabine and capecitabine in patients with advanced biliary cancer...
  4. doi request reprint Sorafenib: a clinical and pharmacologic review
    Renuka Iyer
    Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Expert Opin Pharmacother 11:1943-55. 2010
    ..Sorafenib is approved for the treatment of advanced inoperable hepatocellular cancer and advanced renal cell cancer...
  5. ncbi request reprint Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease
    Renuka V Iyer
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Biol Blood Marrow Transplant 11:587-92. 2005
    ..Multiple courses may be necessary to achieve or maintain response in some patients, and prolonged BDP therapy is a feasible alternative to prolonged systemic corticosteroids...
  6. ncbi request reprint Surgical resection after TNFerade therapy for locally advanced pancreatic cancer
    Manpreet K Chadha
    Department of Medicine, Roswell Park Cancer Institute and State University of New York at Buffalo, Buffalo, NY, USA
    JOP 10:535-8. 2009
    ..Transfection of tumor cells with TNFerade maximizes the antitumor effect of TNF-alpha under influence of radiation leading to synergistic effects in preclinical studies...
  7. ncbi request reprint Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report
    Anubha Bharthuar
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    JOP 10:523-7. 2009
    ..When present simultaneously, they pose a therapeutic challenge given the many available targeted agents with reported efficacy in renal cell cancer and limited options for metastatic pancreatic cancer...
  8. ncbi request reprint Chemoradiation is a tolerable therapy for older adults with esophageal cancer
    Sujatha Nallapareddy
    Roswell Park Cancer Institute, Elm and Carlton Sts, Buffalo, NY 14263, USA
    Anticancer Res 25:3055-60. 2005
    ..Ten-20% of EC patients are over the age of 75 years. There are limited data regarding efficacy and tolerability of CRT for the treatment of EC in the elderly...
  9. ncbi request reprint Cystic pancreatic tumors (CPT): predictors of malignant behavior
    Milind Javle
    Department of Medicine, Roswell Park Cancer Institute, and State University at Buffalo, Buffalo, New York 14263, USA
    J Surg Oncol 95:221-8. 2007
    ..The diagnosis of malignancy in CPT cases requires pancreatectomy. Clinical and laboratory characteristics of CPT may predict underlying malignancy...
  10. ncbi request reprint Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer
    Veena Watwe
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Am J Clin Oncol 28:560-4. 2005
    ..Similar data were obtained for EGFR expression before and after chemoradiation...
  11. ncbi request reprint Combined hepatocholangiocarcinoma: case-series and review of literature
    Vishal Bhagat
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Int J Gastrointest Cancer 37:27-34. 2006
    ..In this study we attempted to address this need and review our experience...
  12. ncbi request reprint Gallbladder cancer: Defining the indications for primary radical resection and radical re-resection
    Jason M Foster
    Department of Surgical Oncology, Roswell Park Cancer Institute, State University of New York at Buffalo, Elm and Carlton Streets, Buffalo, New York 14263 0001, USA
    Ann Surg Oncol 14:833-40. 2007
    ..In this review, we present our experience managing gallbladder cancer at a tertiary center by using an aggressive surgical approach for T2 or greater disease, reserving simple cholecystectomy only for T1 lesions...
  13. doi request reprint Current understanding of the molecular biology of pancreatic neuroendocrine tumors
    Jianliang Zhang
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Natl Cancer Inst 105:1005-17. 2013
    ..Further advances in our understanding of the molecular mechanisms of PanNETs and improved preclinical models will assist in developing personalized therapy utilizing novel drugs to provide prolonged control or even cure the disease. ..
  14. doi request reprint Exact tests using two correlated binomial variables in contemporary cancer clinical trials
    Jihnhee Yu
    Department of Biostatistics, University at Buffalo, State University of New York, Buffalo, NY, USA
    Biom J 51:899-914. 2009
    ..The method is easy to implement. It does not increase the sample size over that of the univariate exact test and in most cases reduces the sample size required. Sample size calculations are provided for selected designs...
  15. ncbi request reprint Leptomeningeal metastases from signet ring adenocarcinoma of the cecum
    Manpreet K Chadha
    Department of Medicine, State University of New York, Buffalo and Roswell Park Cancer Institute, Buffalo, NY, USA
    J Clin Oncol 25:5028-9. 2007
  16. ncbi request reprint Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinoma
    Thaer Khoury
    Department of Pathology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Int J Gastrointest Cancer 35:171-7. 2005
    ..Intestinal trefoil peptide (TFF-3) expression has been demonstrated in benign hepatobiliary diseases, but there are limited data regarding its expression in HCC...
  17. pmc Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality
    Suresh Kalathil
    Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Res 73:2435-44. 2013
    ....
  18. pmc Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma
    Guy A Weiss
    Department of Medicine, University at Buffalo, Buffalo, New York, USA
    J Gastrointest Oncol 4:20-9. 2013
    ..This study examined the prevalence of PIK3CA and EGFR mutations in pancreaticobiliary cancer where erlotinib, an EGFR inhibitor, is approved for therapy...
  19. ncbi request reprint Anaplastic pancreatic carcinoma. A case report and review of literature
    Manpreet K Chadha
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    JOP 5:512-5. 2004
    ..It presents as a large cystic mass with loco-regional and distant spread. Three histological types have been described: pleomorphic, spindle cell and sarcomatoid...
  20. doi request reprint Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study
    Nithya Ramnath
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Anticancer Drugs 19:749-52. 2008
    ..However, this approach was associated with higher grade 3/4 neutropenia and is not recommended for further study in metastatic NSCLC...
  21. ncbi request reprint Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil
    Milind M Javle
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Institute, Houston, Texas 77030, USA
    Clin Cancer Res 13:965-71. 2007
    ..Cyclooxygenase-2 inhibitors may ameliorate chemotherapy-induced mucosal toxicity and enhance its antitumor effect. We investigated this hypothesis in the Ward colorectal cancer rat model and in a phase I clinical study...
  22. ncbi request reprint Akt expression may predict favorable prognosis in cholangiocarcinoma
    Milind M Javle
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Gastroenterol Hepatol 21:1744-51. 2006
    ..The aim of this clinicopathological study was to investigate the overexpression and co-expression of EGFR and related signaling proteins in cholangiocarcinoma and explore their relationship to clinical outcome...